
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is a biotech company with promising prospects, as it focuses on the research and development of therapies for multiple types of cancers, viral diseases, and immune-deficiency disorders. Its ongoing Phase 2 clinical trial for Ampligen in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor shows potential for the treatment of metastatic pancreatic cancer, a disease with a high mortality rate. With multiple clinical trials underway and a current focus on pancreatic cancer, AIM ImmunoTech presents a high risk-high reward opportunity for investors.
Bears say
AIM ImmunoTech is currently facing several challenges such as balance sheet/liquidity risks, lack of commercial success for its product candidates, and strong competition in the biotech industry. Additionally, upcoming clinical data releases may not meet expectations, further impacting investor sentiment and ability to gain regulatory approvals. The company will need to address these issues and demonstrate strong clinical success in order to improve its outlook and attain its share price target.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares